Key clinical point: CD4+ T-cell reactivation and interleukin-2 release are responsible for acute gastrointestinal symptoms when patients with celiac disease are exposed to gluten.
Major finding: Following intradermal injection with gluten peptides, IL-2 levels increased by 272-fold within 4 hours.
Study details: Two phase 1 studies involving 28 patients with celiac disease.
Disclosures: The study was supported by the University of Chicago Celiac Disease Center and the University of Oslo KG Jebsen Coeliac Disease Research Centre. The investigators reported additional relationships with several government and nonprofit organizations. Multiple investigators are employees of ImmusanT, which is developing Nexvax2.
Goel G et al. Science Advances. Aug 7. doi: 10.1126/sciadv.aaw7756.